Market Overview

UPDATE: Goldman Sachs Raises PT to $32 on Pfizer on Breakup Optionality

Related PFE
Will The New Pfizer Be A Winner? SunTrust Analyst Thinks So, Upgrades Stock
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Biotechs Weaken, But These Names Have Bullish Charts (Investor's Business Daily)

Goldman Sachs maintained Pfizer, Inc. (NYSE: PFE) with a Buy rating and raises the price target from $30.00 to $32.00.

Goldman Sachs commented, "PFE reported 4Q12 earnings and gave 2013 financial guidance which included highlighting efforts to optimize both the innovation-driven and value-based businesses as distinct entities. On the conference call, PFE management described the two businesses as already being distinct in developed markets. While the two businesses are intertwined in Emerging Markets – which works well in these high-growth geographies – PFE will consider separating the two business models in these markets as they evolve. This potential move supports our long held view that PFE could unlock substantially greater value by breaking up the business into two separately traded companies."

Pfizer closed at $27.70 on Tuesday.

Latest Ratings for PFE

Nov 2015SunTrust Robinson HumphreyUpgradesReduceNeutral
Nov 2015Argus ResearchMaintainsBuy
Oct 2015Cowen & CompanyUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters